0.00Open17.61Pre Close0 Volume0 Open Interest103.00Strike Price0.00Turnover0.00%IV-2.46%PremiumJan 3, 2025Expiry Date19.66Intrinsic Value100Multiplier-4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.73Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Money Thrill OP : Novo Nordisk climbed more than "3% in Copenhagen", following an upgrade of the pharmaceutical company's advice from 'neutral' to 'BUY', despite a sharply lowered target price from 1,100 to 750 Danish crowns. The broker lowered its target after CagriSema, but judged the wave of selling on the stock to be exaggerated. 'Novo remains the most exciting growth story in the EU pharmaceutical industry and is now reasonably valued,' it judges.